RenovaroCube to Present Cutting-Edge Cancer Diagnostics Research at European Society for Medical Oncology Congress
RenovaroCube (NASDAQ: RENB), an AI-driven cancer profiling innovator, will present two scientific studies at the European Society for Medical Oncology (ESMO) Congress on September 15, 2024. The presentations showcase:
1. A deep learning model using cell-free DNA fragmentation features to detect cancer from small blood samples, performing on par with state-of-the-art models.
2. The platform's ability to correlate methylation patterns from cancer tissue in cfDNA from plasma, enabling cancer detection through blood samples instead of invasive biopsies.
These advancements support RenovaroCube's strategy to develop an open-source AI platform for potential partners and hospitals, as well as commercialize proprietary diagnostic products. The company aims to accelerate early cancer detection, predict treatment responses, and monitor treatment efficacy using only one vial of blood.
RenovaroCube (NASDAQ: RENB), un innovatore nella profilazione del cancro guidato dall'IA, presenterà due studi scientifici al Congresso della Società Europea di Oncologia Medica (ESMO) il 15 settembre 2024. Le presentazioni mostrano:
1. Un modello di deep learning che utilizza caratteristiche della frammentazione del DNA libero per rilevare il cancro da piccoli campioni di sangue, esibendo prestazioni pari ai modelli più avanzati.
2. La capacità della piattaforma di correlare i modelli di metilazione dei tessuti tumorali nel cfDNA proveniente dal plasma, permettendo la rilevazione del cancro attraverso campioni di sangue anziché biopsie invasive.
Questi progressi supportano la strategia di RenovaroCube di sviluppare una piattaforma AI open-source per potenziali partner e ospedali, oltre a commercializzare prodotti diagnostici proprietari. L'azienda mira ad accelerare la rilevazione precoce del cancro, prevedere le risposte ai trattamenti e monitorare l'efficacia dei trattamenti utilizzando solo un flacone di sangue.
RenovaroCube (NASDAQ: RENB), un innovador en la profilación del cáncer impulsado por IA, presentará dos estudios científicos en el Congreso de la Sociedad Europea de Oncología Médica (ESMO) el 15 de septiembre de 2024. Las presentaciones destacan:
1. Un modelo de aprendizaje profundo que utiliza características de fragmentación de ADN libre para detectar cáncer a partir de pequeñas muestras de sangre, mostrando un rendimiento comparable a los modelos más avanzados.
2. La capacidad de la plataforma para correlacionar patrones de metilación de tejido canceroso en cfDNA proveniente del plasma, lo que permite la detección de cáncer a través de muestras de sangre en lugar de biopsias invasivas.
Estos avances apoyan la estrategia de RenovaroCube para desarrollar una plataforma de IA de código abierto para socios potenciales y hospitales, así como para comercializar productos de diagnóstico propios. La empresa tiene como objetivo acelerar la detección temprana del cáncer, predecir respuestas al tratamiento y monitorear la eficacia del tratamiento utilizando solo un vial de sangre.
RenovaroCube (NASDAQ: RENB)는 AI 기반의 암 프로파일링 혁신 기업으로, 2024년 9월 15일 유럽 의학 종양학회(ESMO) 총회에서 두 가지 과학 연구를 발표할 예정입니다. 발표 내용은 다음과 같습니다:
1. 세포 유리 DNA 파편화 특성을 이용한 딥 러닝 모델로, 작은 혈액 샘플에서 암을 탐지하며 최신 모델과 동등한 성능을 보여줍니다.
2. cfDNA의 혈장 내 암 조직의 메틸화 패턴을 상관지을 수 있는 플랫폼의 능력으로, 침습적인 생검 대신 혈액 샘플을 통해 암을 탐지할 수 있습니다.
이러한 발전은 RenovaroCube의 개방형 AI 플랫폼 개발 전략을 지원하며, 잠재적인 파트너와 병원에 제공하고, 독점 진단 제품을 상용화하는 것을 목표로 합니다. 회사는 단 한 병의 혈액만으로 조기 암 발견, 치료 반응 예측 및 치료 효능 모니터링을 가속화하는 것을 목표로 하고 있습니다.
RenovaroCube (NASDAQ: RENB), un innovateur dans le profilage du cancer guidé par l'IA, présentera deux études scientifiques au Congrès de la Société Européenne d'Oncologie Médicale (ESMO) le 15 septembre 2024. Les présentations mettront en avant :
1. Un modèle d'apprentissage profond utilisant des caractéristiques de fragmentation de l'ADN libre pour détecter le cancer à partir de petits échantillons de sang, obtenant des performances comparables aux modèles les plus avancés.
2. La capacité de la plateforme à corréler les motifs de méthylation des tissus cancéreux dans le cfDNA provenant du plasma, permettant la détection du cancer par le biais d'échantillons de sang au lieu de biopsies invasives.
Ces avancées soutiennent la stratégie de RenovaroCube de développer une plateforme IA open-source pour des partenaires et des hôpitaux potentiels, ainsi que de commercialiser des produits de diagnostic propriétaires. L'entreprise vise à accélérer la détection précoce du cancer, à prédire les réponses aux traitements et à surveiller l'efficacité des traitements en utilisant uniquement un flacon de sang.
RenovaroCube (NASDAQ: RENB), ein KI-gesteuertes Unternehmen zur Krebsprofilierung, wird am 15. September 2024 zwei wissenschaftliche Studien auf dem Kongress der Europäischen Gesellschaft für Medizinische Onkologie (ESMO) präsentieren. Die Präsentationen beinhalten:
1. Ein Deep-Learning-Modell, das Eigenschaften der Fragmentierung von zellfreiem DNA verwendet, um Krebs aus kleinen Blutproben zu erkennen, das mit den modernsten Modellen vergleichbar ist.
2. Die Fähigkeit der Plattform, Methylierungsmuster von Krebsgewebe im cfDNA aus Plasma zu korrelieren, ermöglicht die Krebsdetektion mittels Blutproben anstelle von invasiven Biopsien.
Diese Fortschritte unterstützen die Strategie von RenovaroCube, eine Open-Source-KI-Plattform für potenzielle Partner und Krankenhäuser zu entwickeln sowie proprietäre Diagnostikprodukte zu kommerzialisieren. Das Unternehmen zielt darauf ab, die frühe Krebsdetektion zu beschleunigen, Behandlungsergebnisse vorherzusagen und die Wirksamkeit der Behandlung mit nur einem Blutvial zu überwachen.
- None.
- None.
AMSTERDAM, Sept. 13, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: RENB) RenovaroCube (Cube, the Company), a leading AI-driven innovator using multi-omics technology for cancer profiling, is pleased to announce two scientific presentations at a leading cancer conference – the European Society for Medical Oncology (ESMO) Congress – on September 15, 2024.
“Combined, the findings that will be showcased represent key steps along the developmental pathway of Cube’s “go-to-market” strategy for its open-source AI platform as a service provider to many potential private sector partners and (academic) hospitals, as well as commercializing proprietary diagnostic products. This is only the beginning of our journey towards cutting-edge medical achievements,” said Dr. Dennis Makarawung, MD, PhD, the Company’s Medical Director.
One presentation describes the development of a deep learning model that leverages cell-free DNA (cfDNA) fragmentation features (fragmentomics) from a small sample of blood to detect cancer. The results show that in comparison to state-of-the-art cfDNA cancer detection models, we were able to perform on par while utilizing only minute amounts of genetic data. The integration of fragmentomics into the Cube’s current platform, further enhances its capacity to detect cancer, potentially leading to earlier and/or better treatment options and improved patient outcomes.
A second study demonstrated the Cube platform’s ability to correlate methylation patterns from cancer tissue in cfDNA derived from plasma, indicating that cancer can be detected in blood samples as an alternative for invasive tissue biopsies.
Dr. Henk Vietor, the Company’s Managing Director, said: “We believe Cube is at the forefront of developing a cutting edge, multi-omics platform designed to substantially accelerate liquid biopsy diagnostics using only 1 vial of blood. By integrating advanced AI/ML algorithms with comprehensive molecular data, Cube aims to accelerate early cancer detection, predict treatment responses, monitor treatment efficacy, and screen for recurrence. The data presented at ESMO give us the opportunity to showcase our AI/ML platform's capabilities and to demonstrate how our innovative approaches are paving the way for advancements in cancer diagnostics.
About Renovaro
Renovaro aims to accelerate precision and personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better-targeted treatments, and drug discovery. Renovaro Inc. includes RenovaroBio with its advanced cell-gene immunotherapy company and RenovaroCube.
RenovaroCube has developed an award-winning AI platform that is committed to the early detection of cancer and its recurrence and monitoring subsequent treatments. RenovaroCube intervenes at a stage where potential therapy can be most effective. RenovaroCube is a molecular data science company with a background in FinTech and a 10-year history. It brings together proprietary artificial intelligence (AI) technology, multi-omics, multi-modal data, and the expertise of a carefully selected multidisciplinary team to radically accelerate precision medicine and enable breakthrough changes in cancer care.
About ESMO
ESMO is the European Society for Medical Oncology. Representing more than 35,000 oncology professionals in 172 countries, ESMO is a reference for oncology education and information. ESMO’s core mission is to improve the quality of cancer care, from prevention and diagnosis all the way to palliative care and patient follow-up. It is to educate – doctors, cancer patients and the general public – on the best practices and latest advances in oncology. And it is to promote equal access to optimal cancer care for all patients.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties, including but not limited to the success or efficacy of our pipeline, platform and fundraising. All statements other than historical facts are forward-looking statements, which can be identified by the use of forward-looking terminology such as “believes,” “plans,” “expects,” “aims,” “intends,” “potential,” or similar expressions. Actual events or results may differ materially from those projected in any of such statements due to various uncertainties, including as set forth in Renovaro’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Renovaro Inc. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For media inquiries, please contact: karen@renovarocube.com
Source: Renovaro Inc.
FAQ
What research will RenovaroCube (RENB) present at the ESMO Congress on September 15, 2024?
How does RenovaroCube's (RENB) cancer detection model compare to current methods?
What is the significance of RenovaroCube's (RENB) methylation pattern study?
What is RenovaroCube's (RENB) goal for their multi-omics platform?
